Výsledky vyhledávání - "Kenna Lynn Anderes"

KRYSTAL-1: Activity and safety of adagrasib (MRTX849) in patients with advanced/metastatic non–small cell lung cancer (NSCLC) harboring a KRASG12C mutation

Publikováno v: Journal of Clinical Oncology. 40:9002-9002

9002 Background: KRAS is a key mediator of the RAS/MAPK signaling cascade that promotes cellular growth and proliferation. KRASG12C mutation occurs in ̃14% of NSCLC. Adagrasib, an investigational agent, is a KRASG12C inhibitor that irreversibly and

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9188386804b27bfbb4981eb65c487616
https://doi.org/10.1200/jco.2022.40.16_suppl.9002

Zobrazit plný text záznamu

Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors

Autor: Gerald Steven Falchook, Luis H. Camacho, Goldy C. George, David S. Hong, Siqing Fu, Wen Liu, Kirk S. Culotta, Aung Naing, Kenna Lynn Anderes, Sarina Anne Piha-Paul, Jennifer J. Wheler, Susan Percy Ivy, Stacy Moulder, Suhendan Ekmekcioglu, Razelle Kurzrock, Yuejin Wen, Apostolia Maria Tsimberidou, Ignacio Garrido-Laguna, Darren W. Davis

Publikováno v: Cancer. 120:2164-2173

BACKGROUND The current study was conducted to evaluate the safety and biological activity of dual inhibition of the vascular endothelial growth factor (VEGF) pathway with combined bevacizumab and cediranib (a VEGF receptor tyrosine kinase inhibitor).

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::bff10f3f3b9b5592cf99f45b4a3ee79f
https://doi.org/10.1002/cncr.28701

Zobrazit plný text záznamu

Abstract A079: Subpopulation heterogeneity demonstrated in circulating tumor cells isolated from breast cancer patients using ApoStream, an antibody-independent cancer cell recovery device

Autor: Vishal Gupta, Darren W. Davis, Vladislava O. Melnikova, Dave Hasegawa, Kenna Lynn Anderes

Publikováno v: Molecular Cancer Research. 11:A079-A079

Background: Current established methods of circulating tumor cell (CTC) isolation and identification rely on antibodies against epithelial specific markers such as epithelial cell adhesion molecule (EpCAM) and cytokeratin (CK). The classical phenotyp

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f360e74fcb25bce92c90d3ca21fd449d
https://doi.org/10.1158/1557-3125.advbc-a079

Zobrazit plný text záznamu

Etirinotecan pegol (EP) target-specific pharmacodynamic (PD) biomarkers measured in circulating tumor cells (CTCs) from patients in the phase III BEACON study in patients with metastatic breast cancer (mBC)

Autor: Chris Twelves, Seock-Ah Im, Alison L. Hannah, Ahmad Awada, Katie Caygill, Hope S. Rugo, Edith A. Perez, Darren W. Davis, Javier Cortez, Kenna Lynn Anderes, Ute Hoch, Joyce O'Shaughnessy, Binghe Xu, Dennis G. Fry, Yen Lin Chia

Publikováno v: Journal of Clinical Oncology. 31:1087-1087

1087 Background: EP is a unique topoisomerase 1 inhibitor that provides continuous exposure to SN38. EP demonstrated a 29% overall response rate in patients with mBC, leading to a phase III global BEACON study in patients with mBC. CTCs in patient bl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::db102b0b85ea1a668321592f080cf4ea
https://doi.org/10.1200/jco.2013.31.15_suppl.1087

Zobrazit plný text záznamu

Development of a quantitative immunofluorescent method for analysis of nuclear and cytoplasmic p53 and p21 in circulating tumor cells (CTC) as biomarkers of response to p53-targeted therapy

Autor: Vladislava O. Melnikova, Darren W. Davis, Weiguo Wu, Kenna Lynn Anderes, Jacky Woo

Publikováno v: Journal of Clinical Oncology. 30:e13575-e13575

e13575 Background: The tumor suppressor p53 is involved in many aspects of cell cycle control and p53 mutations are the most common genetic abnormality in solid tumors. Several diverse approaches targeting p53 signaling including activators of p53, c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::aff40c65997b959490113437ffcfbd91
https://doi.org/10.1200/jco.2012.30.15_suppl.e13575

Zobrazit plný text záznamu

Expression of eIF4E relevant biomarkers detected in circulating tumor cells from metastatic NSCLC and prostate cancer patients using antibody-independent ApoStream technology

Autor: T. Jesse Kwoh, Elizabeth J. Ackermann, Kenna Lynn Anderes, Vishal Gupta, Elena Jouravleva, Weiguo Wu, Jacky Woo, Margaret Pace, Vladislava O. Melnikova, Darren W. Davis

Publikováno v: Journal of Clinical Oncology. 30:e13562-e13562

e13562 Background: Enumeration of circulating tumor cells (CTCs) is used clinically to monitor disease progression and has previously been shown to be an independent biomarker for predicting survival of metastatic breast, prostate, and colorectal can

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::cc7af11e0305cdf7883286daa8679c3c
https://doi.org/10.1200/jco.2012.30.15_suppl.e13562

Zobrazit plný text záznamu

Pharmacodynamic monitoring of DNA damage biomarkers in circulating tumor cells (CTCs) to assess the mechanism of action of the topoisomerase-1 (Topo1) inhibitor, NKTR-102

Autor: Ute Hoch, Kenna Lynn Anderes, Sujita Sukumaran, Christopher Neal, Darren W. Davis, Vladislava O. Melnikova, Christine Taylor Brew, Jacky Woo

Publikováno v: Journal of Clinical Oncology. 30:e13577-e13577

e13577 Background: Inhibitors of Topo1 abrogate DNA replication and induce apoptosis in tumor cells. Topo1 inhibitors are effective cancer therapeutics however improved pharmacokinetic profiles have been sought. NKTR-102 is a next generation topoisom

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::451037267eb8c588d5958ba9db6742ba
https://doi.org/10.1200/jco.2012.30.15_suppl.e13577

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání